Literature DB >> 26172079

Neuroprotection of donepezil against morphine-induced apoptosis is mediated through Toll-like receptors.

Alireza Shafie1, Farshid Moradi1, Esmael Izadpanah2, Aram Mokarizadeh3, Mohammad Raman Moloudi4, Mehrnoush Nikzaban5, Kambiz Hassanzadeh6.   

Abstract

Previously, we had shown that donepezil provides anti-apoptotic effects associated with the prevention of morphine tolerance to the analgesic effect. In this regard, the present study aimed to evaluate the molecular mechanisms involved in this effect considering the possible role of Toll-like receptor (TLR) 2,4, and the balance between pre-apoptotic and anti-apoptotic Bcl family proteins. To this end, male Wistar rats received daily morphine in combination with either normal saline or donepezil (0.5, 1, or 1.5 mg/kg, ip). The analgesic effect was assessed by the plantar test apparatus. The latency was recorded when the animal responded to the light stimulus. On the 15th day, when no significant difference was observed between morphine and saline groups in terms of analgesia, the frontal cortex and lumbar spinal cord of the animals were dissected. Then, TLR2 and 4, Bcl2, and Bax mRNA fold changes were calculated using Real-time PCR method. The results indicated no significant analgesic effect in the morphine group compared with the saline treated animals after 15 days of injection, while daily co-administration of donepezil with morphine preserved significant analgesia. Moreover, Quantitative PCR showed that morphine significantly increased TLRs and Bax gene expressions and decreased the anti-apoptotic Bcl2. In contrast, donepezil prevented these morphine induced changes in the mentioned gene expressions. Taken together, the results suggest that the neuroprotective effects of donepezil in attenuating morphine-induced tolerance and apoptosis are mediated by preventing morphine-induced changes in TLR2 and 4 gene expressions.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Morphine tolerance; Toll-like receptor

Mesh:

Substances:

Year:  2015        PMID: 26172079     DOI: 10.1016/j.ejphar.2015.07.027

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Metformin prevents morphine-induced apoptosis in rats with diabetic neuropathy: a possible mechanism for attenuating morphine tolerance.

Authors:  Onur Avci; Ercan Ozdemir; Ahmet Sevki Taskiran; Zeynep Deniz Sahin Inan; Sinan Gursoy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-02       Impact factor: 3.195

2.  Inhibitory effects of cholinesterase inhibitor donepezil on the Kv1.5 potassium channel.

Authors:  Kai Li; Neng Cheng; Xian-Tao Li
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

3.  Lidocaine alleviates morphine tolerance via AMPK-SOCS3-dependent neuroinflammation suppression in the spinal cord.

Authors:  Yan Zhang; Gao-Jian Tao; Liang Hu; Jie Qu; Yuan Han; Guangqin Zhang; Yanning Qian; Chun-Yi Jiang; Wen-Tao Liu
Journal:  J Neuroinflammation       Date:  2017-11-02       Impact factor: 8.322

4.  Dihydroartemisinin alleviates morphine-induced neuroinflammation in BV-2 cells.

Authors:  Sen Guan; Tingting Jin; Shuai Han; Wenjie Fan; Haichen Chu; Yongxin Liang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.

Authors:  Nicolas Kerckhove; David Tougeron; Côme Lepage; Denis Pezet; Karine Le Malicot; Manon Pelkowski; Bruno Pereira; David Balayssac
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

6.  An optimised mouse model of chronic pancreatitis with a combination of ethanol and cerulein.

Authors:  Abbas Ahmadi; Bahram Nikkhoo; Aram Mokarizadeh; Mohammad-Reza Rahmani; Shohreh Fakhari; Mehdi Mohammadi; Ali Jalili
Journal:  Cent Eur J Immunol       Date:  2016-03-24       Impact factor: 2.085

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.